Cynthia Brinson, MD
Family Medicine · Austin, TXNPI 1093766396
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,473 of the $402,360 with a category attached, or 67.0%. Gilead accounts for 68.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $101,560 and has fallen 52.3% since, to $48,481 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $603.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$277K
- Viiv Healthcare Company$117K
- Merck$4K
- Pfizer$2K
- Novo Nordisk$572
- AbbVie$477
- plus $1K from 17 others
Across 2,042 payments — averaging $6628.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.7M
- Gilead$3.4M
- Merck$1.9M
- Viiv Healthcare Company$1.8M
- AbbVie$563K
- Novo Nordisk AS$450K
- plus $1.7M from 12 others
What the payments were for
- Consulting fees$73,28518%
- Speaking & faculty fees$269,47367%
- Travel & lodging$44,42111%
- Food & beverage$15,1324%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 337 | $277,107 |
| Viiv Healthcare Company | 153 | $117,018 |
| Merck | 48 | $4,019 |
| Pfizer | 1 | $2,000 |
| Novo Nordisk | 32 | $572 |
| AbbVie(2 entities) | 31 | $477 |
| EMD Serono, Inc. | 8 | $192 |
| Amgen(2 entities) | 12 | $190 |
| Theratechnologies Inc. | 8 | $182 |
| Hologic Sales And Service, LLC | 6 | $128 |
| Lilly USA, LLC | 7 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Abbott | 3 | $53 |
| Astellas Pharma US Inc | 3 | $50 |
| Boehringer Ingelheim | 2 | $33 |
| GSK | 2 | $32 |
| Novartis | 2 | $32 |
| Globus Medical | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,360 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 28 | $137,233 |
| TivicayDolutegravir Sodium | 49 | $134,230 |
| DescovyEmtricitabine/Tenofov Alafenam | 26 | $77,533 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $62,598 |
| PrezcobixDarunavir/Cobicistat | 23 | $59,612 |
| IsentressRaltegravir Potassium | 24 | $47,670 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $45,917 |
| MounjaroTirzepatide | 32 | $33,726 |
| OzempicSemaglutide | 19 | $21,410 |
| ValacyclovirValacyclovir Hcl | 42 | $1,880 |
| Levothyroxine Sodium | 92 | $1,383 |
| Rosuvastatin Calcium | 89 | $1,192 |
| Estradiol | 17 | $1,145 |
| Omega-3 Acid Ethyl Esters | 12 | $1,095 |
| Bupropion XlBupropion Hcl | 31 | $870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $277,107 | $260,68465 claims |
| Viiv Healthcare CompanyTivicay | $117,018 | $134,23049 claims |
| Johnson & JohnsonPrezcobix | $13 | $59,61223 claims |
| MerckIsentress | $4,019 | $47,67024 claims |
| Lilly USA, LLCMounjaro | $92 | $33,72632 claims |
| Novo NordiskOzempic | $572 | $21,41019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- David WrightAustin$124K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.